Authors
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Exploring Novel Treatment Options in Patients With RRMMThe panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.
Latest:
Patient Case Presentation: Patient on ESA for First-Line Therapy and Not Receiving a Marked Response—What Do You Do Next, and Why?Panelists discuss management strategies for a patient with low-risk myelodysplastic syndrome with erythropoiesis-stimulating agent (ESA) failure, weighing options between initiating luspatercept or escalating ESA dosage while emphasizing the need for thorough evaluation of reversible causes before advancing therapy.
Latest:
Personalized Medicine and Targeted Therapy May Hold Promise in Lung CancerThinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Uterine Transposition May Maintain Fertility Following Pelvic RadiotherapyUterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Future Directions in Advanced Endometrial CarcinomaClosing the discussion on advanced endometrial carcinoma, Dr David O’Malley shares his perspective on the future treatment landscape.
Latest:
Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal DiseaseThis retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.
Latest:
Teclistamab Combo Elicits Enduring Responses in Transplant-Ineligible NDMMPhase 2 data support further evaluation of frontline BCMA/CD3 bispecific antibody combinations in phase 3 trials.
Latest:
Patient Case Presentation: A 69-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Symptomatic Brain MetastasesPanelists discuss how a 69-year-old woman with newly diagnosed EGFR-mutant mNSCLC and symptomatic brain metastases requires immediate multidisciplinary care including steroids, radiation oncology consultation, and potential hospitalization, with treatment approach favoring stereotactic radiosurgery for dominant lesions followed by combination therapy like FLAURA2, while emphasizing that asymptomatic patients might allow for initial tyrosine kinase inhibitor treatment with close monitoring before considering radiation to potentially reduce treatment field and minimize long-term neurotoxicity.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Real-World Data Support Dostarlimab Combo Benefit in RUBY TrialSelect comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Latest:
Best Practices for the Medical Oncology BoardsA group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Latest:
Declan Murphy, MB, BCh, on Rate of Equivocal Findings on PSMA PET/CT in Patients With Prostate CancerMurphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
Latest:
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With CancerImmunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Latest:
Evolving Definitions and Risk Gaps in High-Risk Smoldering Multiple MyelomaExplore the evolving landscape of high-risk smoldering myeloma treatment options and the challenges in patient management and risk assessment.
